Tenax Therapeutics provided an update on its on-going clinical trial of levosimendan. Tenax is conducting a multi-center, double-blind placebo controlled Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction, or PH-HFpEF.
- The first patient has been randomised for US-based specialty pharmaceutical company Tenax Therapeutics, Inc.'s (NASDAQ: TENX) Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), the company said.
Net proceeds from this offering may be used by the company to further its clinical trials and efforts to obtain regulatory approval of levosimendan, research and development, general corporate purposes, working capital as well as potential acquisitions.
Levosimendan, a calcium-sensitising inotrope, is thought to have anti-inflammatory properties which has been postulated to attenuate sepsis-associated cardiac dysfunction; however, the recent LeoPARDS trial does not support its use in sepsis.
Echocardiography showed a severe depression of left ventricle ejection fraction without segmental akinesia and, thus, we started dobutamine infusion that after 2 hours was switched to levosimendan because of severe tachycardia without CI improving.